When MRE11, RAD50 and NBS1 were combined, we observed that survival in patients whose tumours had low MRE11/low RAD50/low RAD50 was significantly lower compared to patients whose tumours had high MRE11/high RAD50/high RAD50 expression (Supplementary Fig. 2). The gene discussed is MRE11; the disease is neoplasm.